Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

This study has been completed.
Symphony Neuro Development Company
Information provided by:
Eisai Inc. Identifier:
First received: August 25, 2004
Last updated: November 6, 2008
Last verified: November 2008
In this phase II study, an investigative (not approved by the FDA) drug called GPI 1485 is being assessed to see if it can help preserve erectile function after prostatectomy.

Condition Intervention Phase
Prostate Cancer
Drug: GPI 1485
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3 Arm, 12-Month Study to Evaluate the Effects of GPI 1485 on Erectile Function in Patients Undergoing Bilateral Nerve-Sparing Radical Retropubic Prostatectomy for Prostatic Carcinoma

Resource links provided by NLM:

Further study details as provided by Eisai Inc.:

Estimated Enrollment: 240
Study Start Date: December 2003
Detailed Description:

This drug has been tested in animals, and was shown to protect nerves from damage and to regrow damaged nerves in these animal studies. Participants will receive either GPI 1485 or a placebo (inactive pill). Participants will begin study medication 3 full days prior to their scheduled surgery.

GPI 1485 will be supplied as an oral tablet formulation to men who are candidates for bilateral nerve-sparing prostatectomies. Participants randomly assigned to receive GPI 1485 will be required to take four tablets four times a day by mouth.

GPI 1485 matching placebo will also be supplied as an oral tablet formulation. Participants randomly assigned to placebo will be required to take 4 placebo tablets four times a day by mouth.

Viagra® will be supplied as oral tablets beginning 1 month post-surgery. Patients can begin Viagra® 1 month post-surgery and may continue use until the end of the study, as needed.

The duration of this study is 12 months which includes 5 office visits to your doctor in addition to the surgery day. During this study you will also have other clinical evaluations including a physical exam, blood work, ECG (tracing of your heart rhythm) and urinalysis.

Participants enrolled in this study will also carry a handheld diary that is loaded with special protocol-specific software, which will be referred to as the patient experience diary (PED). Over the duration of this study, participants will complete their questionnaires and answer questions about their medication compliance in the electronic PED.


Ages Eligible for Study:   40 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Clinical diagnosis of localized prostate carcinoma and scheduled to undergo curative surgical resection via bilateral nerve sparing procedure.
  2. Localized prostate cancer is defined as:

    • Gleason score <=7 (<=3 + <=4)
    • PSA <=10 off of finasteride (Proscar®) and dutasteride (Avodart®)
    • <=T2a stage disease
  3. Motivated males, 40 to 69 years of age inclusive, and in the opinion of the investigator, are currently in a monogamous, sexually active relationship.
  4. Males that have erectile function (EF) (without the use of pharmacotherapy within 30 days prior to screening assessment).
  5. EF is defined as a score of >=26 on the EF domain of the IIEF questionnaire based on patient experiences over the 4 weeks prior to biopsy.
  6. Body Mass Index (BMI) within the 18-34.9 kg/m2 range.
  7. Able to swallow whole tablets equivalent to capsule size 0.
  8. Available for protocol-specified visits and procedures.
  9. Informed written consent must be provided prior to any study-specific procedures.

Exclusion Criteria:

  1. Recent history, within 6 months before screening, of drug or alcohol abuse.
  2. History of peripheral neuropathy.
  3. History of acute or chronic depression that in the opinion of the investigator may interfere with protocol-specified efficacy measurements.
  4. History of diabetes that requires use of insulin or oral hypoglycemic agents, myocardial infarction, or cerebrovascular accident.
  5. History of spinal trauma or surgery to the brain or spinal cord.
  6. Any medical disability or laboratory abnormality (e.g., serum creatinine > 2.0 mg/dL) that, in the opinion of the Investigator, may interfere with the protocol-specified safety and efficacy measurements, present an unacceptable risk to the patient's well-being, or compromise the patient's ability to provide informed consent.
  7. History of pelvic radiation therapy (external beam radiation or brachytherapy).
  8. Concomitant use of hormonal therapy, vasodilators (nitrates), dutasteride (Avodart®) or finasteride (Proscar®) within the 30 days prior to biopsy and throughout the study.
  9. Concomitant use of therapeutic agents to treat ED other than those specified in the protocol is not permitted starting at least 30 days prior to biopsy and continuing throughout the study.
  10. Previous exposure to GPI 1485 (previously AMG-474-00).
  11. Treatment with an investigational agent within the 30 days before screening or scheduled to receive an investigational agent other than that specified by this protocol during the course of this study.
  12. Any contraindication to Viagra® use
  13. Unable to stop the use of inducers or inhibitors of cytochrome P450 (CYP) 3A4 from Baseline until the end of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00090376

  Show 25 Study Locations
Sponsors and Collaborators
Eisai Inc.
Symphony Neuro Development Company
Study Director: Antonella Favit-Van Pelt, MD, PhD Eisai Inc.
  More Information Identifier: NCT00090376     History of Changes
Other Study ID Numbers: 0501-0202
Study First Received: August 25, 2004
Last Updated: November 6, 2008

Keywords provided by Eisai Inc.:
Erectile Dysfunction
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Erectile Dysfunction
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Mental Disorders processed this record on April 25, 2017